Phaos Technology Holdings (Cayman) (POAS) Common Equity (2024 - 2025)

Phaos Technology Holdings (Cayman) posted quarterly Common Equity of -$2.7 million for Q4 2025, down 81.72% on a QoQ basis from -$1.5 million in Q2 2025.

Phaos Technology Holdings (Cayman) (POAS) has 2 years of Common Equity data on file, last reported at -$2.7 million in Q4 2025.

  • For the quarter ending Q4 2025, Common Equity changed N/A year-over-year to -$2.7 million; the trailing twelve-month figure through Oct 2025 stood at -$2.7 million (changed N/A YoY), and the FY2025 full-year result was -$1.5 million, down 169.34% from the prior year.
  • Common Equity for Q4 2025 stood at -$2.7 million, down from -$1.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $2.2 million in Q2 2024 and bottomed at -$2.7 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 52.70 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 22.98 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 48.99 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 26.10 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 10.33 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 2.96 Bn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 10.68 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 7.20 Bn
10 Phaos Technology Holdings (Cayman) 6.83 Mn 6.73 Mn - -2.67 Mn

Historic Data

Download Data 🔒
DateValue
Oct 31, 2025 -2.67 Mn
Apr 30, 2025 -1.47 Mn
Apr 30, 2024 2.17 Mn